Merck & Co Tops Research Investment Index For 2010

BMI View: The leading multinational drugmakers will place downward pressure on their research and development (R&D) budgets over the short term. Cost-cutting and the implementation of operational efficiencies will continue and will be offset partially by commitments to pipeline candidates, especially expensive late-stage clinical trials.

To read the full article, please choose one of the following options: